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Drug-induced QT interval prolongation is one of the most common reasons for the withdrawal of drugs from the market. In
the past decade, at least nine drugs, i.e. terfenadine, astemizole, grepafloxacin, terodiline, droperidol, lidoflazine, sertin-
dole, levomethadyl and cisapride, have been removed from the market or their use has been severely restricted because of
drug-induced QT interval prolongation. Therefore, this irregularity is a major safety concern in the case of drugs submitted
for regulatory approval. The most common mechanism of drug-induced QT interval prolongation may be drug-related
inhibition of the human ether-a ´-go-go-related gene (hERG) channel, which subsequently results in prolongation of the
cardiac action potential duration (APD). hERGAPDbase is a database of electrophysiological experimental data document-
ing potential hERG channel inhibitory actions and the APD-prolongation activities of chemical compounds. All data entries
are manually collected from scientific papers and curated by a person. With hERGAPDbase, we aim to provide useful
information for chemical and pharmacological scientists and enable easy access to electrophysiological experimental
data on chemical compounds.
Database URL: http://www.grt.kyushu-u.ac.jp/hergapdbase/
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Introduction
The QT interval of an electrocardiogram is the measure of
the duration of ventricular depolarization and repolariza-
tion. When ventricular repolarization is delayed and the QT
interval is prolonged, there is increased risk of ventricular
tachyarrhythmia. Ventricular repolarization is determined
by the duration of the cardiac action potential, which is
prolonged because of decreased inactivation of inward
Na
+ or Ca
2+ currents, increased activation of the Ca
2+ cur-
rent, or inhibition of one or more outward K
+ currents. The
rapidly activating components of the delayed rectifier po-
tassium current, known as outward K
+ currents (IKr), seem
to have the most influential role in determining the
duration of the action potential and, thus, the QT interval.
QT interval prolongation induced by drugs is known as
drug-induced QT interval prolongation.
Drug-induced QT interval prolongation has been one of
the most common reasons for the withdrawal of drugs
from the market in the past decade. Drug-induced QT inter-
val prolongation might cause polymorphic ventricular
tachycardia, i.e. ‘torsades de pointes’ (TdP), and TdP may
trigger ventricular fibrillation and sudden death in the
worst-case scenario (1). Therefore, over the past decade,
at least nine drugs, i.e. terfenadine, astemizole, grepaflox-
acin, terodiline, droperidol, lidoflazine, sertindole, levo-
methadyl and cisapride, have been removed from the
market or their use has been severely restricted because
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tion. Interestingly, the chemical structures of these nine
drugs are unrelated, and they are non-cardiovascular drugs.
According to recent research, the human ether-a `-go-go-
related gene (hERG) encodes a pore-forming protein,
which may represent the a-subunit of the human potassium
channels responsible for IKr.
The hERG channel plays an important role in the repo-
larization phase of the action potential. The duration of the
action potential in ventricular cardiocytes determines the
length of the QT interval in surface ECGs. hERG channel
blockers delay repolarization, which prolongs the action
potential duration (APD), and this translates into a pro-
longation of the QT interval.
The most common mechanism of drug-induced QT inter-
val prolongation may be inhibition of the hERG channel by
drugs, and the subsequent prolongation of the APD (2, 3);
in other words, hERG channel blockers may prolong cardiac
action potentials and thus lead to the development of long
QT syndrome (4).
Furthermore, TdP caused by drug-induced QT interval
prolongation is a major safety concern with drugs that
are submitted for regulatory approval. To avoid severe
drug cardiotoxicity, adherence to the International
Conference on Harmonization’s (ICH) S7B guideline
entitled ‘The non-clinical evaluation of the potential for
delayed ventricular repolarization (QT interval prolonga-
tion) by human pharmaceuticals’ is recommended; this in-
volves a non-clinical testing strategy for assessing the
potential of a test substance to delay ventricular repolari-
zation (5, 6).
To address these issues, we propose a unique database—
hERGAPDbase. hERGAPDbase contains electrophysiological
experimental data on chemical compounds with potential
hERG channel-blocking effects, which were measured in
terms of IKr currents in the hERG channel using the
patch–clamp technique. In addition, electrophysiological
experimental data concerning the APD prolongation activ-
ity of chemical compounds will also be included in
hERGAPDbase. These data may be one of the most import-
ant indicators for predicting drug-induced QT interval pro-
longation. All data were manually collected and curated
prior to input into hERGAPDbase.
hERGAPDbase is a web-based interface, which allows
the user to search for chemical compounds with hERG
channel-blocking potential and APD prolongation activity.
hERGAPDbase also displays the top 30 chemical compounds
on the basis of their degree of similarity with the chemical
compound queried by the user, and shows the electro-
physiological experimental data of each compound.
Although Fenichel’s database (http://www.fenichel.net/
pages/Professional/subpages/QT/Tables/pbydrug.htm) and
Polak et al. (7) collected hERG assay data from scientific
papers and the publicly deposited databases for the
assessment of the torsadogenic potency of chemical com-
pounds, there may be no databases accumulating both
hERG and APD assay data. In this context, hERGAPDbase
may be unique.
Thus, hERGAPDbase promotes a better understanding of
drug-induced QT interval prolongation. In the future,
hERGAPDbase might enable scientists to predict not only
the hERG channel-blocking potential of drugs but also the
drugs’ influence on the QT interval in the early stages of
drug research and development.
Data collection
Overall data collection methods for hERGAPDbase are out-
lined in Figure 1. The primary source of data in
hERGAPDbase is published scientific literature. A paper on
hERG assay (8) and another on APD assay (8) were obtained
from PubMed (9). In PubMed, we searched for the key-
words ‘hERG’, ‘IC50’ and the phrase ‘patch clamp’ to find
scientific papers mentioning hERG channel inhibitory activ-
ity for each chemical compound. To collect data regarding
the APD for each chemical compound, we searched for
the phrase ‘action potential duration’ and the keywords
‘APD30’, ‘APD60’ and ‘APD90’. Search profiles to find papers
of interest at PubMed have been developed, improved and
combined with repeated use of these keywords and phrases
(Figure 1A).
After finding papers of interest, three types of informa-
tion—hERG assay data, APD assay data and chemical com-
pound data—were extracted manually (Figure 1B).
hERG assay data, which include characteristics such as
chemical name, IC50, species, host cell, hERG channel-
expression system, experimental temperature and PMID,
are described in detail in Table 1. Although IC50 values
obtained from mammalian cells expressing the hERG chan-
nel are more reliable than those from cells with heteroge-
neous expression of the hERG channel (10, 11), we collected
electrophysiological data from scientific papers in an ob-
jective manner to acquire chemical compound information
with as much structural diversity as possible.
APD assay data, including chemical name, concentration,
species, tissue, cell, measure after perfuse (min), stimulation
(Hz), APD30, APD60, APD90 and PMID are described in
detail in Table 2.
In addition to the hERG and APD assay data, three types
of chemical compound files, i.e. Structure Data Format (SDF)
files and Simplified Molecular Input Line Entry Specification
(SMILES) files were collected from the PubChem database
(12). Joint Photographic Experts Group (JPEG) files were
also collected by converting the format of SDF files by
using MarvinView, which is a freely available software
(http://www.chemaxon.com/download/marvin/).
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pre-processing
The database schema of hERGAPDbase is outlined in
Figure 2.
All hERG and APD assay data were collected independ-
ently from various scientific papers. These experimental
data were related to each other by PMID. However, all
chemical information was manually collected from the
PubChem database based on the chemical name mentioned
in scientific papers. Thus, different chemical names may in-
dicate the same chemical structures. To avoid such incon-
sistencies in chemical names, all chemical information was
converted into the binary bit string, which describes the
chemical compound in SDF and/or SMILES formatted
chemical compound data. These binary bit strings were
added to the searchable FingerPrint (FP) DB, with each
entry related to electrophysiological experimental data,
such as hERG and/or APD assay data.
hERGAPDbase was implemented using the open source
MySQL relational database management system to accu-
mulate hERG assay data (Table 1) and APD assay data
(Table 2).
For quick processing of similarity searches, all chemical
compound data were pre-processed for construction of the
FP DB. First, all SDF and/or SMILES files were converted into
MOL2 files by OpenBabel software (13). OpenBabel, which
is freely available software (http://openbabel.org/), is a spe-
cialized system used mainly for converting chemical file
formats.
PubMed
Papers related
to HERG assay
Papers related
to APD assay
HERG
assay data
APD
assay data
PubChem
Manual curation
(A) Getting
papers
of interest
(B) Information 
extraction by
manual curation
SDF SMILES
Chemical compound data
JPG
Figure 1. Overall method for hERGAPDbase data collection. (A) Two types of papers related to the hERG assay and the APD assay
found in PubMed. (B) hERG assay data and APD assay data were extracted manually from scientific papers. The structural data of
the chemical compounds (SDF; SMILES; and JPEG files) were obtained from PubChem.
Table 1. Description of accumulated hERG assay data
Chemical name Name of chemical compounds and/or drugs described in the scientific papers.
IC50 (mM) The half maximal inhibitory concentration (mM), which is a measure of the effectiveness of a
compound in inhibiting hERG channel current.
Species Origin of the hERG channel gene/protein.
Host cell Cell with natural and/or artificial expression of hERG channel.
HERG channel expression system In vitro hERG channel expression system. For example, ‘transient’ and ‘stable’.
Experimental temperature Experimental temperature for patch–clamp test.
PMID Unique identifier assigned to each PubMed entry.
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Figure 2. Schematic representation of hERGAPDbase architecture. hERGAPDbase consists of five data tables:
PubMed data, Chemical compound data, FP DB, APD assay data and HERG assay data. The abbreviations APD
and HERG indicate APD and hERG, respectively. The PubMed data table consists of two attributes: PubMed
Unique Identifier (PMID) and Link to Abstract. The Chemical compound data table consists of five attributes:
chemical name, Sybyl Mol2 chemical modeller output (MOL2), SDF, SMILES and JPEG). The FP DB data table consists
of two attributes: chemical name and FP. The APD assay data table consists of 11 attributes: PMID, chemical name,
concentration, species, tissues, cell, measure after perfusion, stimulation, APD at 30% repolarization (APD30), APD
at 60% repolarization (APD60) and APD at 90% repolarization (APD90). The HERG assay data table consists of seven
attributes: PMID, chemical name, half maximal inhibitory concentration (IC50; mM), species, host cell, HERG channel
expression system and experimental temperature.
Table 2. Description of accumulated APD assay data
Chemical name Name of chemical compounds and/or drugs described in the scientific papers.
Concentration Concentration of the chemical compounds and/or drugs for measurement
of the action potential.
Species Origin of tissues and cells tested for the action potential of the compounds.
Tissue Tissues for extracting cells.
Cell Cells extracted from tissues for measuring the action potential.
Measure after
perfusion (min)
Time measurement of the action potential after perfusion of compounds.
Stimulation (Hz) Electrical stimulation frequency for the preparation.
APD30 One of the action potential parameters that indicates APD at 30% repolarization.
APD60 One of the action potential parameters that indicates APD at 60% repolarization.
APD90 One of the action potential parameters that indicates APD at 90% repolarization.
PMID Unique identifier assigned to each PubMed entry.
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the mol22aefp module. The mol22aefp module, part of the
MOLPRINT 2D software, is a compiled C binary program
(14). Lastly, all FP files were accumulated into the
hERGAPDbase to create the FP DB, which was used for simi-
larity searching.
Web-based interface of
hERGAPDbase
The web-based interface of hERGAPDbase was built using
open-source Linux–Apache–MySQL–PHP (LAMP) tools and is
outlined in Figure 3. hERGAPDbase is an online interactive
interface for structure-based similarity searching in the FP
DB.
hERGAPDbase query input and
similarity search
Detailed here are descriptions for querying and similarity
searching in the hERGAPDbase, an example of similarity
searching results and a description of how to browse
hERG and APD assay data for each chemical compound.
hERGAPDbase allows the user to specify a chemical com-
pound or a drug using one of the three input methods:
the chemical name, the MOL2 or SDF file or SMILES
(Figure 3B).
In the chemical name window, the user specifies a chem-
ical compound or drug in the pull-down menu. With the
MOL2 or SDF file window, the user uploads the chemical
compound data of any MOL2 or SDF file. In the SMILES
window, the user inputs SMILES-formatted chemical com-
pound data, which are text-based descriptions of chemical
compounds.
After the user queries a chemical compound or drug
as mentioned above and clicks on the search button
(Figure 3B), the hERGAPDbase starts a similarity search in
the FP DB.
The similarity search is performed with a perl script, tani-
moto.pl, which is a program of MOLPRINT 2D software.
Tanimoto.pl is an efficient algorithm used to calculate
the similarity between chemical compounds: the higher
the score, the more structural similarity between the
compounds.
Results of the similarity search
After a similarity search, the hERGAPDbase displays table
style results listing the top 30 chemical compounds in order
of their similarity search score (Figure 4). The resulting table
includes the following columns: number (No.), chemical
name, structure, score, hERG channel assay results and
APD assay results.
The attributes listed in the results table—No., chemical
name, structure and score—indicate the compound’s simi-
larity rank among the top 30 compounds, the name
of the chemical compounds, JPG images of the chemical
compounds and the similarity score calculated by tanimo-
to.pl, respectively. In addition, the hERG channel assay
and APD assay results are displayed in the results table.
Both columns include links to the electrophysiological
experimental data or list ‘Data not found’ if there were
no data.
Displaying hERG and APD assay
results
The user can access the hERG assay results (Figure 5) for
each chemical compound through the link in the hERG
channel-assay results column, as shown in Figure 4. As
shown in Figure 5A, the user will find that astemizole in-
hibits the activities of the human hERG channel, which was
stably expressed on HEK 293 cells, with an IC50 value of
0.0013mM. Further, the user will also find that astemizole
inhibits activities of the human hERG channel transiently
expressed in the Xenopus oocyte with an IC50 value of
0.0484mM (Figure 5B).
Next, the user can also access the APD assay results
(Figure 6) of each chemical compound through the link
in the APD assay results column (Figure 4). As shown
in Figure 6A, 0.1mmol/l astemizole had no effect on
APD30, APD60 and APD90 of the guinea-pig ventricular
papillary muscle. Further, 10.0mmol/l astemizole had no
effect on APD30 but prolonged 4.0% of APD60 and
APD90 of the guinea-pig ventricular papillary muscle
(Figure 6B).
Other features of hERGAPDbase
hERGAPDbase provides a platform for downloading chem-
ical compound data through click, the chemical name in the
hERG assay results or the APD assay results (Figure 3D–F).
Through this platform (Figure 3F), the user can copy and
paste SMILES formatted data and JPG files and download
SDF files.
In addition, hERGAPDbase also provides links to
MEDLINE entries for accessing abstracts of scientific
papers related to the experimental data through click
using the PMID (Figure 3G).
Future plans and upgrades
To better understand the torsadogenic activities of chem-
ical compounds, it may be necessary to collect additional
information on chemical compounds for which hERG and
APD assays have been performed. Although, we are
.............................................................................................................................................................................................................................................................................................
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.............................................................................................................................................................................................................................................................................................Figure 3. Overall outline of hERGAPDbase. (A) Homepage of hERGAPDbase. (B) Screen capture of the similarity search homepage
for query input. In this example, astemizole is specified in the pull-down menu. (C) The resulting table from the similarity search
in the FP DB of the hERGAPDbase. (D) Table of the hERG assay data for astemizole in this example. (E) Table of the APD assay
data for astemizole. (F) Platform of data download for SDF, SMILES and JPEG files. (G) Paper abstracts of data resources for the
hERG and APD assays from PubMed.
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compounds that have shown positive hERG and APD
assay effects during electrophysiological experiments, it
may be important to collect information on chemical com-
pounds with negative effects. In addition, the current
version of hERGAPDbase has more hERG assay data than
APD assay data; therefore, more of the latter should be
added.
For these reasons, hERGAPDbase is still under construc-
tion and may have limited usefulness in its current state.
Therefore, hERGAPDbase will be continuously updated
when new articles and data are opened to the public
domain. We plan to increase the number of structurally
unrelated chemical compound data entries by adding
new electrophysiological experimental data. Moreover, in
the future, we plan to collect clinically measured human
ECG data.
Regarding the web-based interface, we plan to provide
users with the ability to download the full data set, which
contains chemical compound information including bio-
activity annotations, for easier access to hERGAPDbase.
In the next version of hERGAPDbase, we also plan
to create bidirectional links between our database
and the major open and public databases, such as
PubChem, for easier and more comprehensive access to
our database.
Figure 4. Screen capture of the similarity search results for astemizole. The attributes listed in the results table, i.e. No., chemical
name, structure, score, hERG channel assay results and APD assay results, indicate the compound’s similarity rank among the top
30 compounds, the name of the chemical compounds, JPG images of the chemical compounds, the similarity score calculated by
tanimoto.pl, hERG assay results and the APD assay results, respectively.
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